Pharma.AI Internal Research Model

Rentosertib, an AI-designed TNIK inhibitor, posts Phase 2a IPF results

Insilico Medicine’s rentosertib (ISM001-055), discovered with generative models, met a Phase 2a safety endpoint in 71 IPF patients; the 60 mg daily arm showed a mean FVC gain of 98.4 ml versus a 20.3 ml decline on placebo.